US 1-877-223-3104  |   Login / Register  |   My Cart  |

Catalog

Recently Viewed

TGEX-HC-hG1-Zeo

MX026
Price (USD): $767.00
+ −

TGEX-HC-hG1-Zeo

Heavy Chain Cloning Vector for the Mammalian Expression of Human IgG1 Antibodies

Technical Description

The TGEX™ vector series is designed for the rapid expression of antibody molecules by transient gene expression in mammalian cell suspension cultures. TGEX™-HC-hG1-Zeo expresses the constant region of the human IgG1 heavy chain. Expression of full length antibody molecules is achieved by co-transfection with a light chain variable region cloned into one of the TGEX™-LC vector series. Using transient transfection technologies yields of antibody between 20 mg/L and 200 mg/L and more in serum-free conditions can be obtained in just a few days.

Applications

  • Mammalian expression of full length antibodies by transient gene expression.

  • Selection of stable transfectants using Zeocin™.

For research use only; not intended for any animal or human therapeutic or diagnostic use.

Specifications

General Characteristics:

Plasmid Size: 5828
Promoter: CMV + TPL
Leader Peptide: pelBK
Cloning Site: Double BsaI
Fusion Protein: full length IgG1 human constant region
Selection: ampicillin (bacteria), zeocin™ (mammalian)
Replication: pMB1 high copy number

Physical Characteristics:

Concentration: 0.5 µg/µl.
Product Size: 10 µg.
Buffer: DNA Conservation Buffer (Tris/HCL 5 mM, EDTA 0.1 mM, pH 8.5, sterile).
Storage Temperature: -20°C.

Quality Control & Certification of Analysis

Product Sequence:

The entire plasmid sequence was confirmed by the Sanger method.

Certification:

Product meets all specifications.

TGEX-HC-hG1-Zeo map

 

TGEX-HC-hG1-Zeo cloning site

 

adobe file icon  TGEX-HC-hG1-Zeo manual

genbank file  TGEX-HC-hG1-Zeo sequence in GenBank format

FASTA file  TGEX-HC-hG1-Zeo sequence in FASTA format

adobe file icon  TGEX-HC-hG1-Zeo MSDS

Citations

  1. O'Connor E, Lachacz E, Delmar J et al. (2025). Development of production methodologies for scFv-Fc conjugated critical reagents to support CAR-T clinical programs. Bioanalysis. 2025; 14:1-16.

  2. Castellano KMG, Luna AM, de Jesús Carballo Uicab G et al. (2025). Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1. MAbs. 2025;17(1):2591461.

  3. Halfmann PJ, Patel RS, Loeffler K et al. (2025). Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice. Nat. Commun. 2025;16(1):462 .

  4. Biswas A, Loeffler K, Kim D et al. (2025). Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses. NPJ Vaccines. 2025; 10(1):225.

  5. McArthur N, Kang B, Rivera Moctezuma FG et al. (2025). Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates. Biotechnol. Prog. 2024;40(5):e3463.

  6. Halfmann PJ, Lee JS, McArthur N et al. (2025). Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variant. NPJ Vaccines. 2025;3(1):19.

  7. Luo NY, Minne RL, Gallant JP et al. (2024). Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer. Bioconjug. Chem. 2024; 35(3):389-399.

  8. Hwang J, Jang IY, Bae E et al. (2024). H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice. Biomed Pharmacother. 2024;176:116781.

  9. Halfmann, P.J., Loeffler, K., Duffy, A. et al. (2024). Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine. Nat Commun. 2024;15, 1284.

  10. Mendoza-Salazar I., Gómez-Castellano KM., González-González E., Gamboa-Suasnavart R., Rodríguez-Luna SD., Santiago-Casas G., Cortés-Paniagua MI., Pérez-Tapia SM., Almagro JC. (2022). Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library. Antibodies (Basel),10;11(1):13.

  11. Pedraza-Escalona M., Guzmán-Bringas O., Arrieta-Oliva HI., Gómez-Castellano K., Salinas-Trujano J., Torres-Flores J., Muñoz-Herrera JC., Camacho-Sandoval R., Contreras-Pineda P., Chacón-Salinas R., Pérez-Tapia SM, Almagro JC. (2021). Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. BMC Infect Dis.,30;21(1):1121.

  12. Mukherjee A., Stathos ME., Varner C., Arsiwala A., Frey S., Hu Y., Smalley DM., Schaffer DV., Kane RS. (2020). One-pot synthesis of heterodimeric agonists that activate the canonical Wnt signaling pathway. Chem. Commun. (Camb) 56(25):3685-3688.